502 related articles for article (PubMed ID: 14691554)
21. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
[TBL] [Abstract][Full Text] [Related]
22. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
23. Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex.
Dong X; Su X; Yu J; Liu J; Shi X; Pan Q; Yang J; Chen J; Li L; Cao H
J Mol Graph Model; 2017 Jan; 71():116-123. PubMed ID: 27902963
[TBL] [Abstract][Full Text] [Related]
24. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
25. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
26. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein.
Kaelin WG
Cancer; 2009 May; 115(10 Suppl):2262-72. PubMed ID: 19402056
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
[TBL] [Abstract][Full Text] [Related]
28. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
29. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV; Ivanov SV; Danilkovitch-Miagkova A; Lerman MI
J Biol Chem; 2001 May; 276(18):15306-15. PubMed ID: 11278694
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis.
Tsao CC; Teh BT; Jonasch E; Shreiber-Agus N; Efstathiou E; Hoang A; Czerniak B; Logothetis C; Corn PG
Cancer Biol Ther; 2008 Oct; 7(10):1619-27. PubMed ID: 19018165
[TBL] [Abstract][Full Text] [Related]
31. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
Shang D; Liu Y; Yang P; Chen Y; Tian Y
Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
[TBL] [Abstract][Full Text] [Related]
32. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
Gao W; Li W; Xiao T; Liu XS; Kaelin WG
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
[TBL] [Abstract][Full Text] [Related]
34. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.
Kim WY; Safran M; Buckley MR; Ebert BL; Glickman J; Bosenberg M; Regan M; Kaelin WG
EMBO J; 2006 Oct; 25(19):4650-62. PubMed ID: 16977322
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice.
Wang J; Ma Y; Jiang H; Zhu H; Liu L; Sun B; Pan S; Krissansen GW; Sun X
J Hepatol; 2011 Aug; 55(2):359-68. PubMed ID: 21168458
[TBL] [Abstract][Full Text] [Related]
36. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
37. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
38. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
39. Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
Pereira T; Zheng X; Ruas JL; Tanimoto K; Poellinger L
J Biol Chem; 2003 Feb; 278(9):6816-23. PubMed ID: 12468553
[TBL] [Abstract][Full Text] [Related]
40. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.
Galbán S; Martindale JL; Mazan-Mamczarz K; López de Silanes I; Fan J; Wang W; Decker J; Gorospe M
Mol Cell Biol; 2003 Oct; 23(20):7083-95. PubMed ID: 14517280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
